Ottawa Heart Institute Research Corporation;L'Institut de Cardiologie de Montréal
发明人:
Patrick VIGNEAULT,Darryl DAVIS,Stanley NATTEL,Sandrine PARENT
申请号：
US16678856
公开号：
US20200172871A1
申请日:
2019.11.08
申请国别(地区):
US
年份:
2020
代理人:
摘要：
There is disclosed a cardiac explant-derived stem cell (EDC), the cell comprising a gene encoding an intermediate-conductance Ca2+-activated K+ channel, and wherein the gene causes an overexpression of the intermediate-conductance Ca2+-activated K+ channel, and methods of producing same. There is also disclosed a method of producing engineered EDCs having a modulated bioelectric property, the method comprising: obtaining EDCs； introducing a KCNN4 gene into the EDCs to increase the expression of KCa3.1 channels, to produce engineered EDCs. There is also disclosed a composition for treating or ameliorating a damaged myocardium in a subject, the composition comprising extracellular vesicles isolated from cultures of engineered EDCs. There is also disclosed a method for treating or ameliorating a damaged myocardium in a subject, comprising administering the engineered EDCs or the extracellular vesicles isolated from cultures of engineered EDCs to the damaged myocardium of the subject.
